Molecular imaging (SPECT/PET) provided a key result in the Phase 2 rember® clinical trial by identifying regions within the brain that were protected by the drug. These regions coincided with areas known to be affected by Alzheimer’s neuropathology and provide significant support for the use of TAIs to treat the disease.
In the images above, created using rCBF SPECT, the central figure demonstrates the locations of tau pathology in Alzheimer’s. The surrounding images show the locations that rember® appears to protect. The areas are the statistically significant regions of difference between the active and control groups.